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ABSTRACT
Therapeutics based on small interfering RNA (siRNA)
have a great clinical potential; however, delivery
problems have limited their clinical efficacy, and
new siRNA delivery vehicles are greatly needed.
In this report, we demonstrate that submicron
particles (800–900nm) composed of the polyketal
PK3 and chloroquine, termed as the PKCNs, can
deliver tumor necrosis factor-a (TNF-a) siRNA
in vivo to Kupffer cells efficiently and inhibit gene
expression in the liver at concentrations as low as
3.5kg/kg. The high delivery efficiency of the PKCNs
arises from the unique properties of PK3, which
can protect siRNA from serum nucleases, stimulate
cell uptake and trigger a colloid osmotic disruption
of the phagosome and release encapsulated siRNA
into the cell cytoplasm. We anticipate numerous
applications of the PKCNs for siRNA delivery to
macrophages, given their high delivery efficiency,
and the central role of macrophages in causing
diseases such as hepatitis, liver cirrhosis and
chronic renal disease.
INTRODUCTION
The development of delivery vehicles that can eﬃciently
deliver small interfering RNA (siRNA) in vivo remains a
major challenge in the ﬁeld of biotechnology (1–3).
Delivering siRNA in vivo has been challenging because
of its rapid hydrolysis by serum nucleases, membrane
impermeability and sequestration in lysosomes after
endocytosis (4,5). At present, siRNA delivery vehicles
have been based around ‘soft materials’, which are
composed of electrostatically held complexes, com-
posed of cationic lipids or polycations (6–10). These
delivery vehicles have had limited success in vivo,
because they are easily destroyed by either charged
serum proteins, the high shear forces in the blood or
in cell lysosomes after endocytosis, and generally
require high doses for eﬃcacy in animals (>200mg/kg
siRNA) (6–8). In this report, we demonstrate that solid
polymeric particles composed of the acid-sensitive
polymer PK3 and chloroquine, termed as the PKCNs,
can deliver siRNA to macrophages and inhibit gene
expression in vivo at concentrations as low as 3.5mg/kg.
In contrast to cationic lipid or polycation siRNA
complexes, the PKCNs are ‘hard’ materials, composed
of the water-insoluble polymer PK3, and should
maintain their integrity in vivo because of the high ener-
getic cost of exposing PK3 to water. We anticipate
numerous applications of the PKCNs given their high
delivery eﬃcacy and the central role of macrophages in
human diseases.
MATERIALS AND METHODS
Materials
Double-stranded tumor necrosis factor-a (TNF-a) siRNA
(mouse) (sense strand: 50-GAC AAC CAA CUA GUG
GUG CUU-30) and scrambled siRNA (sense strand:
50-GCG UCG UCA GUA CCA GGA AUU-30) were
synthesized by Dharmacon (Lafayette, CO, USA).
Enzyme-linked immunosorbent assay (ELISA) kit
(TNF-a ELISA Ready-Set-Go) for the detection of
TNF-a was purchased from eBioscience (San Diego, CA,
USA) and alanine aminotransferase (ALT) assay kit was
purchased from Pointe Scientiﬁc Inc. (Canton, MI, USA).
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP;
chloride salt) was purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA). Lipofectamine2000 was
purchased from Invitrogen (Carlsbad, CA, USA).
Lipofectamine2000 and siRNA were formulated into
Lipofectamine–siRNA complexes [5:1 (w/w)] following
the manufacture’s instructions. All other chemicals were
purchased from Sigma-Aldrich (St Louis, MO, USA) and
used as received unless otherwise speciﬁed.
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PK3 was synthesized as described in Yang et al. (11).
Brieﬂy, the diols, cyclohexanedimethanol (1.04g,
7.25mmol) and 1,5-pentanediol (0.19g, 1.81mmol) were
dissolved in 20ml of distilled benzene at 100 C.
Recrystallized p-toluenesulfonic acid (5.5mg,
0.029mmol) was dissolved in ethyl acetate (500ml) and
added to the benzene solution. The polymerization
reaction was initiated by the addition of 2,2-dimethoxy-
propane (0.94g, 9.06mmol). Additional 2,2-dimethoxy-
propane (500ml) and benzene (2ml) were subsequently
added to the reaction to compensate for 2,2-dimethoxy-
propane and benzene that had distilled oﬀ. After 24h,
the reaction was stopped with triethylamine (100ml) and
isolated by precipitation in hexanes. The number average
molecular weight of PK3 was 2530Da (polydispersity
index: 1.43) as determined by gel permeation chromatog-
raphy, using a Shimadzu system (Kyoto, Japan).
Preparation and characterization of siRNA-loaded
PKCNs
PK3 (40mg) with or without chloroquine (1mg) was
added to 1ml of methylene chloride containing either an
ion-paired DOTAP–siRNA complex (1.0mg siRNA and
2.2mg DOTAP) or ﬂuorescein-labeled siRNA (Fl-siRNA)
ion-paired with DOTAP (12). The mixture of PK3 and
DOTAP–siRNA complex was emulsiﬁed by homogeniza-
tion (24200r.p.m., 30s) into 8ml of a 5% (w/v) aqueous
polyvinyl alcohol (PVA) solution. The resulting emulsion
was then poured into 20ml of 0.5% PVA solution, and the
methylene chloride was removed with a rotary evaporator.
The resulting particles were isolated by centrifugation
(10000g for 10min), washed twice and freeze-dried.
Particle size and shape were determined by dynamic
light scattering (DLS) using a 90plus particle size
analyzer (Brookhaven, Holtsville, NY, USA) and
scanning electron microscopy (SEM) using a Hitachi
S-800 SEM (Hitachi, Pleasanton, CA, USA). In order to
determine loading eﬃciency of siRNA in the PKCNs, the
PKCNs (2.0mg) containing Fl-siRNA were dispersed in
HCl solution (0.12M) and incubated until the PKCNs
hydrolyzed completely. After neutralized with NaOH
solution (0.12M), the ﬂuorescence of the total Fl-siRNA
released from the PKCNs was measured using a
ﬂuorometer (lex/lem=494/510nm) and compared with
the initial ﬂuorescence of the Fl-siRNA used in making
the particles. Poly(lactic-co-glycolic acid) (PLGA)
particles containing chloroquine and siRNA were
formulated exactly the same way as the PKCNs except
the polymer PLGA was used instead of PK3 [RG 503H,
35.4kDa (polydispersity index: 2.5), Boehringer
Ingelheim].
The release of siRNA from the PKCNs in vitro
The release of siRNA from the PKCNs was evaluated
using Fl-siRNA. Fl-siRNA-loaded PKCNs (1.5mg) were
suspended in either pH 5.0 or 7.4 buﬀer solutions (1.0ml).
For statistical analysis, three independent samples per
group were prepared. The suspensions were kept at 37 C
under gentle shaking. At speciﬁc time points, the
suspensions were centrifuged at 12000g for 2min,
and the ﬂuorescence of the supernatants was then
analyzed with a Shimadzu spectroﬂuorophotometer
(Kyoto, Japan) (lex/lem=494/510nm). The pellets were
re-suspended with fresh buﬀer solutions (1.0ml) and the
procedure was repeated for each time point.
In vitro uptake of the PKCNs by macrophages
RAW264.7 macrophages (ATCC number: TIB-71) from
the American Type Culture Collection (ATCC)
(Manassas, VA, USA) were maintained at 37 C under a
humidiﬁed atmosphere of 5% CO2 in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) containing 10%
(v/v) fetal bovine serum (FBS), supplemented with peni-
cillin (100U/ml) and streptomycin (100mg/ml). Human
umbilical vein endothelial cells (HUVECs; Genlantis; a
gift from Dr Gang Bao) were cultured in endothelial
cell growth medium (Genlantis) supplemented with 20%
FBS, 13.3U/ml heparin, 40mg/ml endothelial mitogen
(Biomedical Technologies), 1% l-glutamine and penicillin
and streptomycin. For ﬂow cytometry, the macrophages
(1 10
6 cells/well, 12-well plate) and HUVECs (1 10
6
cells/well, 12-well plate) were incubated with free Fl-
siRNA, DOTAP–Fl-siRNA, Lipofectamine–Fl-siRNA
or PKCN–Fl-siRNA (183.4pmol siRNA in each sample)
for 4h. Cells were washed three times with ice cold
phosphate-buﬀered saline (PBS) and scraped into tubes
for ﬂow cytometry. The ﬂuorescent cell population was
measured by ﬂow cytometer (BD LSR ﬂow cytometer;
BD Bioscience, San Jose, CA, USA) using a laser for
ﬂuorescein (lex/lem=494/510nm).
Confocal microscopy of siRNA delivered by the PKCNs
We investigated the intracellular distribution of siRNA
delivered by the PKCNs to macrophages, using confocal
microscopy. Macrophages (RAW264.7) were grown on
chambered coverglasses (No. 1.5) and treated with either
free Fl-siRNA, DOTAP–Fl-siRNA, Lipofectamine–Fl-
siRNA or PKCN–Fl-siRNA (183.4pmol siRNA in each
sample) for 10min, 30min, 1h and 2h. After each time
point, the macrophages were washed three times with PBS
and imaged with a confocal microscope (Zeiss LSM 510;
Carl Zeiss Inc., Thornwood, NJ, USA).
Serum stability of siRNA in the PKCNs
The ability of the PKCNs to protect encapsulated
siRNA from serum nucleases was investigated with
electrophoresis, using ﬂuorescein-labeled siRNA.
siRNA samples, either free Fl-siRNA, DOTAP–Fl-
siRNA, Lipofectamine–Fl-siRNA or PKCN–Fl-siRNA
(468.5pmol siRNA in each sample), were prepared in
nuclease-free water (100ml) and added to a 100mlo f
90% FBS. The siRNA samples were incubated at 37 C
for 24h, and then 10ml of a 10% sodium dodecyl sulfate
solution was added to them and the mixtures were heat-
denatured for 5min at 100 C. The siRNA from the
samples were isolated by hot phenol extraction followed
by ethanol precipitation. An aliquot of each sample
(93.8pmol per lane) was loaded on a 10–20%
e145 Nucleic Acids Research, 2009,Vol.37, No. 22 PAGE 2 OF 10polyacrylamide gel (Lonza, Rockland, ME, USA) and
the electrophoresis was performed at 100V for 40min.
Gels were stained with ethidium bromide (0.1mg/ml)
and visualized by ChemiDoc XRS system (Bio-Rad
Laboratories, Hercules, CA, USA).
In vivo biodistribution of the PKCNs
The biodistribution of the PKCNs was determined using
Fl-siRNA. PKCNs encapsulating Fl-siRNA were
formulated as described above. Either PKCN–Fl-siRNA
(35mg/kg siRNA) or DOTAP–Fl-siRNA complexes
(35mg/kg siRNA) were injected into three mice, respec-
tively, via a jugular vein injection. The mice were sacriﬁced
after 2h and perfused using PBS (150mM, pH 7.4). All
organs were collected and placed in 5ml of 20% (v/v)
Triton X-100 and 80% (v/v) PBS (150mM, pH 7.4). The
organs were homogenized at 12000r.p.m. for 2min and
centrifuged at 5000r.p.m. for 5min. The ﬂuorescence of
ﬂuorescein in the supernatant was then measured at
494nm excitation and 510nm emission, and the ﬂuores-
cence from the organs of saline-injected mice was used as
background. The ﬂuorescent intensity of each organ was
calculated based on the tissue weight.
Delivery of TNF-a siRNA with the PKCNs in vitro
RAW264.7 macrophages (1 10
5 cells/well, 96-well plate)
in DMEM with 10% FBS were incubated with either
PKCN–TNF-a siRNA, PKCN–scrambled siRNA,
DOTAP–TNF-a siRNA complexes, Lipofectamine–
TNF-a siRNA conjugates or free TNF-a siRNA for 4h.
All samples had 0.75mg/ml of siRNA. The cells were
washed three times and then incubated with fresh
medium for 24h. The cells were stimulated with
100ng/ml lipopolysaccharide (LPS) for 4h to induce
TNF-a. The amount of extracellular TNF-a production
was determined using an ELISA assay kit following the
manufacture’s instructions in the kit.
Cytotoxicity of the PKCNs (MTT reduction assay)
An MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide] reduction assay was performed to
measure the cytotoxicity of the PKCNs. The macrophages
(1 10
5 cells/well, 96-well plate) and HUVECs (1 10
6
cells/well, 12-well plate) were incubated with the PKCNs
for 4h. Cells were treated with the PKCNs at various
particle concentrations (0.1–1mg/ml). Next, 20mlo f
MTT solution (5mg/ml in PBS) was added to each well,
and the cells were incubated for 2h. Then, 200mlo f
dimethyl sulfoxide was added to dissolve the resulting
formazan crystals. After 10min of incubation, the
absorbance at 585nm was measured using an Emax
Microplate reader (Molecular Devices, Sunnyvale, CA,
USA). Percentage cell viability was calculated by
comparing the absorbance of the control cells to that of
PKCN-treated cells.
Hemolysis with the PKCNs in vitro
A hemolysis assay was performed using the erythrocytes
of mice. The erythrocytes were collected by centrifugation
of mouse blood (6ml) at 1500g for 15min and then
washed ﬁve times with isotonic PBS (Dulbecco’s PBS,
Gibco) at pH 7.4. The erythrocytes were resuspended in
either PBS (three parts centrifuged erythrocytes plus 11
parts PBS) or distilled water (three parts centrifuged
erythrocytes plus 11 parts water). The polyketal particle
dispersions were prepared in PBS buﬀer with various
concentrations (0.01–1mg/ml). The erythrocyte stock dis-
persion (100ml) was added to 1ml of the polyketal particle
dispersions. One milliliter of PBS without polyketal
particles was used as the negative control (0% hemolysis),
and 1ml of distilled water was used as the positive control
(100% hemolysis). The solutions were mixed and
incubated for 4h at 37 C in an incubator shaker and
centrifuged at 13000r.p.m. for 15min. The percentage
of hemolysis was measured by UV–Vis analysis of the
supernatant at 394nm absorbance.
In vivo delivery of TNF-a siRNA with the PKCNs
A mouse model of acute liver failure was used to evaluate
the ability of the PKCNs to deliver siRNA in vivo;6 -t o8 -
week-old female BALB/c mice were obtained from
Jackson Laboratory (Bar Harbor, Maine). All procedures
used in the animal studies were approved by the
Institutional Animal Care and Use Committee at the
Georgia Institute of Technology. Mice were anesthetized
by isoﬂuorane inhalation and were injected with either
PKCN-TNF-a siRNA, PKCN–scrambled siRNA,
DOTAP–TNF-a siRNA complexes, Lipofectamine–
TNF-a siRNA conjugates or free TNF-a siRNA (either
35mg/kg or 3.5mg/kg siRNA) via a jugular vein injection.
Immediately after the siRNA injection, LPS (2.5mg/kg)
from Escherichia coli 0111:B4 and 700mg/kg D-galactos-
amine (GalN, 100ml) were injected to induce acute liver
failure via an intraperitoneal (i.p.) injection. After 24h,
blood was collected from the mice by a cardiac puncture
and centrifuged at 4000r.p.m. for 15min. Plasma ALT
levels were measured for liver function analysis using an
ALT assay kit (Pointe Scientiﬁc Inc., Canton, MI, USA)
and plasma TNF-a levels were also measured using an
ELISA assay kit, using the protocols provided in the kit.
For liver histology, livers were collected and frozen in
optimal cutting temperature (OCT) solution. OCT
solution-embedded livers were sliced to 10-mm sections
using a Microm Cryo-Star HM 560MV Cryostat, and
liver sections were stained with hematoxylin and eosin.
For statistical analysis, all experiments were performed
using six mice per group unless otherwise speciﬁed.
Signiﬁcance of results was determined via the paired
t-test with P<0.05.
Immunostaining of Kupﬀer cells in the liver
The ability of the PKCNs to target macrophages was
determined qualitatively using immunohistochemistry.
DiI (1,10-dioctadecyl-3,3,3030-tetramethylindocarbocyanine
perchlorate) [12.5% (w/w)]-loaded PKCNs (0.1mg/
mouse) were injected via a jugular vein injection and
after 2h, the livers were collected and preserved in OCT.
The cryoprotective livers were then sliced into 10-m
sections as described above. The 10-mm sections were
PAGE 3 OF 10 Nucleic Acids Research, 2009,Vol.37, No. 22 e145ﬁxed in ice-cold acetone for 2min and rehydrated in tris-
buﬀered saline (TBS, pH 7.0). To reduce nonspeciﬁc
staining, the sections were incubated with 5% FBS in
TBS for 30min at room temperature. In order to visualize
Kupﬀer cells, the sections were incubated with FITC-
labeled anti-mouse F4/80 antigen (1:50; eBioscience) for
30min. The sections were washed for another 10min in
TBS and imaged with a ﬂuorescence microscope (Nikon
E600, Nikon, Melville, NY, USA).
RESULTS AND DISCUSSION
The PKCNs are a new delivery vehicle, designed to deliver
siRNA to macrophages, they are composed of the acid-
sensitive polymer PK3 and chloroquine. The mechanism
by which the PKCNs are formulated and function are
described in Figure 1. The PKCNs are formulated via a
single emulsion solvent evaporation procedure, generating
submicron particles, which have a donut shape. The
PKCNs are designed to protect siRNA from serum
nucleases, but after phagocytosis disrupt the phagosome
and release siRNA into the cytoplasm. The PKCNs have
this multifunctional capability because of the pH sensitiv-
ity of the ketal linkages in PK3 and chloroquine. PK3 has
a hydrolysis half life of 1.8 days at pH 4.5 and 39 days
at pH 7.4; therefore, the PKCNs should maintain their
integrity at pH 7.4, but after phagocytosis, hydrolyze
and cause an osmotic imbalance in the phagosome,
leading to release of siRNA into the cytoplasm. The
PKCNs can be freeze-dried and stored as a solid powder
and also have excellent tissue biocompatibility because of
their neutral degradation products. In summary, the
PKCNs are a multifunctional siRNA delivery vehicle,
which has the physical/chemical properties needed for
translation into clinical trials.
We investigated the pH-sensitive release kinetics of
siRNA from the PKCNs to understand their behavior in
the pH 7.4 environment of the blood and the acidic
phagosome. Figure 2A demonstrates that the PKCNs
release siRNA in a stimuli-responsive manner, at pH 7.4
they encapsulate siRNA with high stability, releasing
only 20% after 48h. In contrast, at pH 5.0 siRNA is
rapidly released from the PKCNs, releasing 50% of the
encapsulated siRNA within 7h. Thus, the PKCNs should
be able to protect siRNA from serum components and
then release them after entering the acidic environment
of the phagosome.
We performed experiments to determine if the PKCNs
could enhance the delivery of siRNA into macrophages by
phagocytosis in the presence of serum in vitro and in vivo.
siRNA
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Figure 1. The PKCNs: a new siRNA delivery vehicle based on solid particles with high eﬃciency in vivo.( A) siRNA is encapsulated into the PKCNs
via a single emulsion/solvent evaporation procedure, generating submicron particles (800–900nm). (B) The PKCNs are injected into mice via a
jugular vein injection and deliver siRNA to macrophages in vivo with high eﬃciency, due to their ability to protect siRNA from serum proteins,
stimulate phagocytosis and disrupt phagosomes. (1) The PKCNs are phagocytosed by macrophages and traﬃcked into phagosomes; (2) the PKCNs
degrade in the acidic environment of the phagosome because of the ketal linkages in PK3, and disrupt the phagosome via a colloid osmotic
mechanism; and (3) siRNA is released into the cytoplasm.
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with Fl-siRNA and incubated with macrophages
(RAW264.7) or endothelial cells (HUVEC) in 10%
serum. The uptake of siRNA was then measured by ﬂow
cytometry and compared against macrophages incubated
with Fl-siRNA complexed with either DOTAP (a cationic
lipid) (DOTAP–Fl-siRNA) or Lipofectamine2000
(Lipofectamine–Fl-siRNA). Figure 2B and C demons-
trates that DOTAP–Fl-siRNA or Lipofectamine–Fl-
siRNA by itself is ineﬃcient at delivering Fl-siRNA into
macrophages in the presence of serum, presumably due to
their rapid degradation by serum proteins. In contrast,
the PKCNs were two to three orders of magnitude more
eﬀective at delivering Fl-siRNA into macrophages than
DOTAP–Fl-siRNA complexes. The PKCNs, therefore,
have the physical stability needed to promote uptake
through the phagocytic pathway in the presence of
serum proteins.
We also investigated if the PKCNs could simi-
larly enhance the uptake of siRNA in vivo. Mice
were injected, via the jugular vein, with either
PKCNs containing Fl-siRNA (PKCN–Fl-siRNA) or
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Figure 2. The PKCNs are a pH-sensitive delivery vehicle that can enhance the uptake of siRNA in vitro and in vivo.( A) Accumulated release of
Fl-siRNA from the PKCNs at phagosomal pH (pH 5.0) (black squares) and physiological pH (pH 7.4) (white circles) (each data represented as
mean±SD). (B) Enhanced cellular uptake of the PKCNs by macrophages in vitro (ﬂow cytometry): macrophages (RAW264.7) were incubated with
PKCNs encapsulating Fl-siRNA (solid line), DOTAP–Fl-siRNA complex (dashed line) and no treatment (shaded line) in DMEM with 10% FBS.
All siRNA samples have 0.75mg/ml siRNA. (C) Mean ﬂuorescence of macrophages treated with PKCNs encapsulating Fl-siRNA and other delivery
vehicles. Mean ﬂuorescence was obtained by ﬂow cytometry (mean±SD). Statistical diﬀerence was performed between HUVEC and macrophages in
microparticle uptake with P<0.05 (asterisk). (D) In vivo biodistribution of PKCNs containing Fl-siRNA (35mg/kg siRNA) (black bars) and
DOTAP–Fl-siRNA complex (35mg/kg siRNA; white bars) (mean±SE); samples were injected into the jugular vein of mice (three mice per
group), and the organs were collected and assayed after 2h. Statistical diﬀerence of biodistribution was performed between PKCN–Fl-siRNA
and DOTAP–Fl-siRNA in each organs with P<0.05 (asterisks). (E) PKCNs protected siRNA from serum nucleases, whereas siRNA complexed
with DOTAP and Lipofectamine degraded in serum. Samples were incubated in 37 C for 24h. Lane 1: intact siRNA as a control; lane 2: free siRNA
in nuclease-free water; lane 3: free siRNA in serum; lane 4: DOTAP–siRNA complex in nuclease-free water; lane 5: DOTAP–siRNA complex in
serum; lane 6: Lipofectamine–siRNA conjugates in nuclease-free water; lane 7: Lipofectamine–siRNA conjugates in serum; lane 8: PKCN–siRNA in
nuclease-free water; and lane 9: PKCN–siRNA in serum.
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the injected siRNA was then determined after 2h.
Figure 2D demonstrates that the PKCNs are capable of
concentrating siRNA into tissues (liver and lung) with
high macrophage content, suggesting that the PKCNs are
eﬃciently taken up by phagocytosis in vivo. In contrast,
DOTAP–Fl-siRNA complexes were relatively ineﬃcient
in delivering siRNA in vivo presumably because of their
rapid degradation in serum. For example, mice treated
with PKCN–Fl-siRNA had a 4-fold higher ﬂuorescence
in liver than DOTAP–Fl-siRNA.
A key requirement for the successful delivery of siRNA
in vivo is protection of the siRNA from serum nucleases.
We therefore investigated if the PKCNs could protect
encapsulated siRNA from serum nucleases. siRNA
samples, free siRNA, DOTAP-siRNA, Lipofectamine
2000-siRNA, and PKCN–siRNA particles were incubated
in either FBS or nuclease-free water at 37 C for 24h and
then analyzed by polyacrylamide gel electrophoresis.
Figure 2E demonstrates that the PKCNs can protect
siRNA from serum nucleases, presumably due to their
solid nature, which prevents nucleases from accessing the
siRNA. In contrast, self-assembled complexes of cationic
lipids, such as DOTAP and Lipofectamine2000, were not
able to protect siRNA from serum nucleases.
We investigated if the PKCNs could deliver functional
siRNA into macrophages and inhibit gene expression
in vitro and in vivo. siRNA targeting TNF-a siRNA was
encapsulated into the PKCNs (Table 1), and their ability
to inhibit TNF-a production from macrophages stimula-
ted with LPS was investigated. The TNF-a siRNA
sequence encapsulated in the PKCNs was originally
developed by Sørensen et al. (13), who used this
sequence to inhibit TNF-a gene expression in mice after
an LPS injection. Figure 3A demonstrates that the
PKCNs can signiﬁcantly improve the functional delivery
of siRNA therapeutics to macrophages in 10% serum. For
example, at a concentration of 0.75mg/ml siRNA, PKCN–
TNF-a siRNA inhibited TNF-a production from
macrophages by 80%, whereas DOTAP–TNF-a siRNA
complexes and free TNF-a siRNA, at the same siRNA
concentration, had no inhibitory eﬀect, presumably
because of their rapid degradation in serum and low
uptake (4–6). PKCNs, which encapsulated scrambled
siRNA, also had no inhibitory eﬀect on TNF-a produc-
tion from macrophages.
The cytoplasmic delivery of siRNA is also a major
challenge in the delivery of siRNA. This is particularly
important with macrophages, which rapidly degrade
phagocytosed materials in their phagosomes. The
PKCNs contain the endosomal disruptive molecule
chloroquine, which should augment the delivery of
siRNA. We investigated if chloroquine within the
PKCNs enhanced the delivery of siRNA to macrophages
in cell culture. Macrophages were incubated with either
PKCN–TNF-a siRNA or PK3–TNF-a siRNA particles
(without chloroquine) in 10% serum, stimulated with
LPS, and then analyzed for TNF-a production.
Figure 3B demonstrates that chloroquine enhances the
delivery eﬃciency of the PKCNs. For example, at a con-
centration of 1mg/ml siRNA, PKCN–TNF-a siRNA
inhibited TNF-a production from macrophages by
80%, in contrast PK3–TNF-a siRNA particles without
chloroquine caused only a 50% inhibition of TNF-a pro-
duction. We performed further confocal microscopy
experiments to determine if the PKCNs could deliver
siRNA to the cytoplasm of macrophages. Confocal micro-
scopy has been widely used to measure the intracellular
distribution and eﬃcacy of siRNA delivery vehicles, these
studies demonstrate that optimal gene inhibition occurs
when siRNA is delivered into the cytoplasm (14,15).
Figure 3C demonstrates that RAW264.7 macrophages
have internalized particles within 10min of incubation
and that these particles appear to be in phagosomes,
based on their punctate appearance. However, after 2h
the cellular ﬂuorescence distribution is dramatically
altered, and now appears to diﬀuse through the cytoplasm,
suggesting that the siRNAs have entered the cytoplasm.
We performed experiments with macrophages,
endothelial cells and red blood cells, to determine the
toxicity proﬁle of the PKCNs. Macrophages and endo-
thelial cells were incubated with various concentrations
of the PKCNs, and cellular toxicity was determined with
the MTT assay. Figure 3D demonstrates that the PKCNs
caused no cellular toxicity to macrophages at a 0.1mg/ml
concentration, which is the concentration required for
80% inhibition of TNF-a production (in cell culture).
The PKCNs also did not cause any cellular toxicity to
HUVECs at concentrations up to 1.0mg/ml. We also
investigated the eﬀects of the PKCNs on red blood cell
membranes. The hemolysis of red blood cells is a common
problem with drug delivery vehicles, particularly
microparticles and cationic lipid-based delivery vehicles.
Figure 3E demonstrates that the PKCNs do not induce
hemolysis of RBCs at a concentration of 0.1mg/ml, and
that even at a high concentration of 1mg/ml they only
induced 34% hemolysis.
The ability of the PKCNs to enhance the delivery of
TNF-a targeted siRNA in vivo was investigated in a
mouse model of LPS-induced acute liver failure. Acute
liver failure causes thousands of deaths each year and
strategies that can enhance the treatment of acute liver
failure are greatly needed. TNF-a secreted by Kupﬀer
cells (liver macrophages) plays a major role in the devel-
opment of acute liver failure, and we therefore
Table 1. Loading eﬃciency of siRNA in PK3 or PLGA particles and
particle sizes
Submicron
particles
PK3–siRNA
particle without
chloroquine
PK3–siRNA
particle with
chloroquine
(PKCN–siRNA)
PLGA–siRNA
particle with
chloroquine
Average loading
eﬃciency (%)
a
42.43 59.05 47.95
Particle size (nm)
b 934.2±59.3 887.7±56.7 881.0±514.9
aThe loading eﬃciency of Fl-siRNA in the PKCNs was determined
by ﬂuorescence of ﬂuorescein (lex/lem=494/518nm). Loading eﬃ-
ciency (%)=(amount of Fl-siRNA loaded in submicron particle)/
(initial amount of Fl-siRNA used to make submicron particle) 100.
bParticle size was determined by DLS (mean±SD).
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siRNA, targeted against TNF-a and alleviate acute liver
failure. Acute liver failure was induced by an i.p. injection
of LPS (2.5mg/kg) and GalN (700mg/kg), and siRNA
samples were injected via a jugular vein injection.
Figure 4A demonstrates that freeze-dried PKCNs can
enhance the eﬃcacy of TNF-a siRNA in vivo, inhibit
TNF-a production and improve the therapeutic outcome
of acute liver failure. For example, at a concentration of
35mg/kg, PKCN–TNF-a siRNA reduced TNF-a levels in
the serum to baseline levels, during LPS-induced acute
liver failure. In contrast, PKCNs with scrambled siRNA,
DOTAP–TNF-a siRNA, Lipofectamine–TNF-a siRNA
or free TNF-a siRNA had no eﬀect on serum levels of
TNF-a. PKCN–TNF-a siRNA was also able to reduce
the pathologic eﬀects of LPS-induced liver failure. For
example, at a concentration of 35mg/kg, PKCN–TNF-a
siRNA reduced the serum ALT values by 69.1%, whereas
free TNF-a siRNA and PKCNs with scrambled siRNA
(35mg/kg siRNA) had no eﬀect on reducing ALT levels
(Figure 4B). Finally, histology sections of LPS-treated
mice demonstrated that PKCNs with TNF-a siRNA pro-
tected the liver from LPS-induced liver damage, whereas
PKCNs with scrambled siRNA, DOTAP–TNF-a siRNA
complex or free TNF-a siRNA could not save hepatocytes
from LPS-induced liver damage (Figure 4C).
We performed further experiments to determine if
the high eﬃcacy of the PKCNs was due to their ‘hard’
solid nature that enhances their serum stability or if
their acid-catalyzed degradation after phagocytosis was
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Figure 3. The PKCNs can deliver siRNA to RAW264.7 macrophages eﬃciently in serum with low cytotoxicity, and chloroquine enhances their
eﬃcacy (all data given as mean±SD). (A) The PKCNs reduced extracellular TNF-a from LPS-stimulated macrophage by 80%; macrophages were
treated with either PKCN–TNF-a siRNA (0.1mg/ml), PK3–TNF-a siRNA particles (without chloroquine) (0.1mg/ml) or DOTAP–TNF-a siRNA
complex (3.25mg/ml) for 4h. Cells were washed three times and TNF-a production was measured using an ELISA kit. All siRNA samples have
0.75mg/ml siRNA. Signiﬁcance of results was determined via the paired t-test between the PKCN–TNF-a siRNA and other delivery vehicles with
P<0.05 (asterisks). (B) Chloroquine enhances the eﬃcacy of siRNA delivery: PKCN–TNF-a siRNA (black bars) and PK3–TNF-a siRNA particles
(without chloroquine) (striped bars). Macrophages were treated with siRNA samples for 4h. Cells were washed three times and TNF-a production
was measured using an ELISA kit. Statistical diﬀerence was performed between PKCN–TNF-a siRNA and PK3–TNF-a siRNA particles (without
chloroquine) at each concentration with P<0.05 (asterisks). (C) Uptake of PKCNs by RAW264.7 macrophages with time in vitro (confocal
microscopy). (D) PKCN–TNF-a siRNA caused no cellular toxicity at a concentration (0.1mg/ml PKCN–TNF-a siRNA) required for 80% inhibition
of TNF-a production (MTT assay). Macrophages (black bars) and HUVEC (white bars) were treated with PKCN–TNF-a siRNA for 4h.
(E) Hemolytic activity of PKCNs.
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submicron particles, containing chloroquine and TNF-a
siRNA (PLGA–chloroquine–TNF-a siRNA), could also
deliver siRNA to Kupﬀer cells in vivo, and compared their
eﬃcacy to the PKCNs. Figure 5A and B demonstrates
that the acid sensitivity of the PKCNs is critical for
in vivo eﬃcacy, for example at a TNF-a siRNA dose of
3.5mg/kg, PKCN–TNF-a siRNA-reduced serum ALT
levels by 59.0% and serum TNF-a values by 96.0%,
whereas PLGA–chloroquine–TNF-a siRNA had no
eﬀect presumably, because of their slower hydrolysis
kinetics (16,17). At the same siRNA concentration,
Lipofectamine–TNF-a siRNA had no eﬀect on ALT
and TNF-a levels.
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Figure 4. The PKCNs enhance the delivery of siRNA in vivo. Mice were injected with LPS (2.5mg/kg) and GalN (700mg/kg) i.p. to induce acute
liver failure and injected with siRNA samples (35mg/kg siRNA) via the jugular vein. The livers and blood of the mice were collected and assayed at
24h after siRNA treatment. (A) PKCNs containing TNF-a siRNA reduce TNF-a levels in the serum to baseline levels (ELISA assay; TNF-a
concentration in serum) (mean±SE). Signiﬁcance of results was determined via the paired t-test between the PKCN–TNF-a siRNA and other
delivery vehicles with P<0.05 (asterisks). (B) PKCNs containing TNF-a siRNA reduce the serum ALT values (mean±SE). Signiﬁcance of results
was determined via the paired t-test between the PKCN–TNF-a siRNA and other delivery vehicles with P<0.05 (asterisks). (C) Liver histology
study using hematoxylin and eosin staining (tissue thickness sliced: 10mm; magniﬁcation objectives:  40) indicates that only PKCNs with TNF-a
siRNA can protect the liver from LPS-induced liver damage.
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development of acute liver failure. The ability of the
PKCNs to target Kupﬀer cells in vivo was therefore deter-
mined using PKCNs that encapsulated the ﬂuorescent dye
DiI. DiI–PKCNs were injected into mice via the jugular
vein, and after 2h the mice were harvested and analyzed
by histology for Kupﬀer cell staining. Figure 5C
demonstrates that the DiI–PKCNs are localized in
Kupﬀer cells after a systemic injection of DiI–PKCNs,
whereas DiI–PKCNs (orange color) were not found in
hepatocytes (dark area—no green color).
In summary, in this report we present a new siRNA
delivery vehicle termed as the PKCNs, which can eﬃ-
ciently deliver siRNA to macrophages in vivo.I n
contrast to delivery vehicles composed of cationic lipids
or polycations, the PKCNs are ‘hard’ materials composed
of water-insoluble polymers and have a strong thermo-
dynamic driving force to maintain their integrity in vivo.
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Figure 5. The PKCNs can deliver siRNA with high eﬃciency in vivo and the acid sensitivity of the PKCNs is critical for in vivo eﬃcacy. Mice were
injected with LPS (2.5mg/kg) and GalN (700mg/kg) i.p. to induce acute liver failure and injected with siRNA samples (3.5mg/kg siRNA) via the
jugular vein. Serum TNF-a concentration and ALT activity were measured at 24h after treatment with siRNA samples. Signiﬁcance of results was
determined via the paired t-test between the PKCN–TNF-a siRNA and other delivery vehicles with P<0.05 (asterisks). (A) The PKCNs reduced
serum TNF-a values, whereas PLGA submicron particles had no eﬀect. TNF-a concentration in the plasma was measured by ELISA (mean±SE).
(B) The PKCNs reduced serum ALT levels (mean±SE), whereas PLGA submicron particles had no eﬀect. (C) The PKCNs were localized in
Kupﬀer cells. FITC-labeled F4/80 antibody (Pan macrophage marker) was used for Kupﬀer cell staining. DiI-loaded PKCNs (orange color) were
taken up by Kupﬀer cells (green color) in vivo—white arrows. No PKCNs were found in hepatocytes—dark area (no green color). The picture was
imaged by ﬂuorescence microscopy ( 20).
PAGE 9 OF 10 Nucleic Acids Research, 2009,Vol.37, No. 22 e145The PKCNs are acid sensitive, and hydrolyze after
phagocytosis in the acidic environment of the phagosome,
allowing them to rapidly release siRNA after cell internal-
ization and potentially disrupt the phagosome through a
colloid osmotic mechanism. The PKCNs were able to
deliver TNF-a siRNA to Kupﬀer cells (liver macrophages)
in vivo and rescue hepatocytes from LPS-induced toxicity
at an siRNA dose of 3.5mg/kg. Based on these obser-
vations, we anticipate numerous uses of the PKCNs for
siRNA delivery to macrophages in vivo.
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